Jan. 22, 2025 – Anthos Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapies to treat cardiovascular metabolic diseases, founded by Blackstone Life Sciences, has published the results of the landmark AZALEA-TIMI 71 study in the January 23 issue of the New England Journal of Medicine (NEJM). 

Jan. 22, 2025 — Public Responsibility in Medicine and Research (PRIM&R) recently called for establishing clear ethical guidelines to ensure data research is conducted responsibly. PRIM&R’s statement is part of the national nonprofit’s comment submission to the National Telecommunications and Information Administration (NTIA), regarding the potential development of ethical guidelines for research using “pervasive data.”

Jan. 9, 2025 — Gender-based racism through microaggressions may be linked to higher blood pressure postpartum and beyond, according to new research published  in Hypertension, a peer-reviewed journal of the American Heart Association.

Jan. 13, 2025 — Medtronic plc recently announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension.

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk of stroke, atrial fibrillation and heart failure, while current pipe use was associated with increased risk of heart failure. Users of smokeless tobacco products had increased risk for myocardial infarction and mortality due to coronary heart disease.

Jan. 13, 2025 – R3 Vascular Inc., a medical device company dedicated to treating peripheral arterial disease (PAD), recently announce it received WCG Institutional Review Board (IRB) approval for the ELITE-BTK Pivotal Trial of its MAGNITUDEÒ Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease (PAD). 

A new study reports persistent disparities in outcomes for people with peripheral artery disease (PAD) and its more severe form, chronic limb-threatening ischemia (CLTI) in the United States.

Jan. 13, 2025 -- ERS Genomics, the CRISPR licensing company, has announced the launch of its Express License platform to provide small research enterprises and startups with affordable and rapid access to the world’s largest foundational and essential CRISPR/Cas9 patent portfolio.

Jan. 8, 2025 — Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, has announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) Application for a Phase 2 clinical trial to evaluate the effect of lorundrostat in the treatment of subjects with moderate-to-severe obstructive sleep apnea (OSA) and hypertension. The Company anticipates initiating the trial in the first quarter of 2025.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now